M&A in the Contract Manufacturing Industry: Implications and Outlook

Description

This report is the fifth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

This 53-page report gives important, expert insight you won't find in any other source. 12 tables and 19 figures throughout the report illustrate major points and trends. This report is required reading for -

CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking

Reasons to Buy

Overview of M&A in the Pharma CMO Industry
Detailed view of CDMO performance by number of deals, based on GlobalData's Deals database
Analysis of M&A and private equity investment by target's specific manufacturing services

Product Code: GDPS0050MAR

Executive Summary
Players
Technology Briefing
Deal types.
Trends
Industry Analysis
Objectives and methodology
Overview of M&A activity 2023
Target characteristics
Acquirer characteristics
Geography
Top acquirers
Biosynth acquires Celares and Pepceuticals
IPCA Laboratories invests in Unichem
Target segment close-ups
Multi
API-small molecule
API-biologic
Commercial dose manufacturing
Deal advisors.
Top financial advisors
Top legal advisors
Valuations
Facility acquisitions
What it means
Drug shortages drive low-tech small molecule deals.
Multi-service and injectable manufacturers targeted
Catalent acquisition shakes up pharma and CMO landscape.
Biologic acquisitions decreased in 2023 but strong interest remains, despite BIOSECURE Act complicating manufacturing agreements
Private equity investments declined
The outlook for M&A
API - biologic targets
API - cell and gene therapy targets
Value Chain
Companies